Survival prognosis in advanced HER-2 negative gastric cancer treated with immunochemotherapy: A novel model

Figure 1 Kaplan-Meier analysis for progression-free survival and overall survival in advanced gastric cancer patients receiving immunotherapy combined with chemotherapy. A: Kaplan-Meier analysis for progression-free survival in advanced gastric cancer patients receiving immunotherapy combined with chemotherapy; B: Kaplan-Meier analysis for overall survival in advanced gastric cancer patients receiving immunotherapy combined with chemotherapy. CI: Confidence interval.

Figure 2 The construction of the nomogram. A: The nomogram for predicting the 3-month and 6-month progression-free survival; B: The nomogram for predicting the 12-month, 15-month, and 18-month overall survival. PD-L1: Programmed cell death ligand 1; MMR: Mismatch repair; dMMR: Deficient mismatch repair; pMMR: Proficient mismatch repair; NLR: Neutrophil-to-lymphocyte ratio; CALLY: C-reactive protein-albumin-lymphocyte; PFS: Progression-free survival; OS: Overall survival.

Figure 3 The evaluation of the nomogram for predicting progression-free survival. A: Graph showing the training set and validation set receiver operating characteristic evaluation plots for 3-month prognostic prediction model; B: Graph showing the training set and validation set receiver operating characteristic evaluation plots for 6-month prognostic prediction model. AUC: Area under the curve; CI: Confidence interval.

Figure 4 The evaluation of the nomogram for predicting overall survival. A: Graph showing the training set and validation set receiver operating characteristic (ROC) evaluation plots for 12-month prognostic prediction model; B: Graph showing the training set and validation set ROC evaluation plots for 15-month prognostic prediction model; C: Graph showing the training set and validation set ROC evaluation plots for 18-month prognostic prediction model. AUC: Area under the curve; CI: Confidence interval.

Figure 5 Graph illustrating the calibration plots for a prognostic model. A: Calibration plots for the training set 3-month progression-free survival (PFS); B: Calibration plots for the validation set 3-month PFS; C: Calibration plots for the training set 6-month PFS; D: Calibration plots for the validation set 6-month PFS; E: Calibration plots for the training set 12-month overall survival (OS); F: Calibration plots for the validation set 12-month OS; G: Calibration plots for the training set 15-month OS; H: Calibration plots for the validation set 15-month OS; I: Calibration plots for the training set 18-month OS; J: Calibration plots for the validation set 18-month OS.